Etofenamate-d4
(Synonyms: 依托芬那酯 d4) 目录号 : GC47323
An internal standard for the quantification of etofenamate
Cas No.:1329837-73-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Etofenamate-d4 is intended for use as an internal standard for the quantification of etofenamate by GC- or LC-MS. Etofenamate is a non-steroidal anti-inflammatory drug (NSAID) and diethylene glycol ester form of flufenamic acid that has anti-inflammatory and analgesic activities.1,2 It inhibits lipoxygenase isolated from guinea pig leukocytes (IC50 = 5.3 μM) and the production of prostaglandin E2 in stimulated rat peritoneal macrophages.2 In vivo, etofenamate reduces acetic acid-induced vascular permeability in mice and UV-induced erythema in guinea pigs in a dose-dependent manner at doses ranging from 40-320 and 5-20 mg/kg, respectively.1 Etofenamate (40 mg/kg per day for 21 days) inhibits inflammation in a rat model of adjuvant-induced arthritis. It also decreases the pain response in a silver nitrate-induced rat model of arthritis and the acetic acid-induced writhing test in mice, indicating analgesic activity. Formulations containing etofenamate have been used in the treatment of osteoarthritis.
1.Nakamura, H., Motoyoshi, S., Imazu, C., et al.Anti-inflammatory, analgesic and anti-pyretic activities of a non-steroidal anti-inflammatory drug, etofenamate, in experimental animalsNihon Yakurigaku Zasshi.80(2)125-135(1982) 2.Nakamura, H., Motoyoshi, S., Ishii, K., et al.The mode of anti-inflammatory action of a topical non-steroidal anti-inflammatory drug, etofenamateNihon Yakurigaku Zasshi.89(1)15-24(1987)
| Cas No. | 1329837-73-1 | SDF | |
| 别名 | 依托芬那酯 d4 | ||
| Canonical SMILES | OCCOCCOC(C1=C(NC2=CC(C(F)(F)F)=CC=C2)C([2H])=C([2H])C([2H])=C1[2H])=O | ||
| 分子式 | C18H14D4F3NO4 | 分子量 | 373.4 |
| 溶解度 | Acetonitrile: soluble,Methanol: soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6781 mL | 13.3905 mL | 26.7809 mL |
| 5 mM | 0.5356 mL | 2.6781 mL | 5.3562 mL |
| 10 mM | 0.2678 mL | 1.339 mL | 2.6781 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。